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ABSTRACT 
The occurrence and clinical impact of herpes simplex virus (HSV) were evaluated in 342 
bronchoalveolar lavage (BAL) specimens from 237 patients. HSV-1 and HSV-2 were 
detected in 32.1% and <1% patients, respectively. A significant difference of HSV-1 
prevalence and load was found in relation to admission to intensive care unit, mechanical 
ventilation, and mortality within 28 days; in particular,  a viral load ≥105 copies/ml BAL was 
significantly associated to critical features. No association was found with immune status 
or other characteristics. HSV-1 was positive in 9/21 (42.9%) cases of ventilator-associated 
pneumonia, with poor outcome in six.  
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Herpes simplex virus (HSV) is a dsDNA virus encompassing two highly seroprevalent 
subtypes, HSV-1 and HSV-2 [1]. In critically ill patients, HSV-1 has been reported in 22-
54% and 16-32% in the upper and lower respiratory tract, respectively [2-6], and 
increasingly associated to pulmonary diseases with poor outcome, particularly in the 
presence of viral load >105 copies/mL bronchoalveolar lavage (BAL)[5,6,7-12]. Moreover, 
HSV-1 has been proposed as a severity marker in ventilator-associated pneumonia 
(VAP)[11]. However, it is unknown whether HSV is a true lung pathogen or its detection 
represents asymptomatic local reactivation in the presence of other pathogens. Herein, we 
prospectively evaluated the occurrence and significance of HSV in 342 consecutive BAL 
specimens from 237 patients (M/F, 149/88; mean age, 56.4 years) over a 12-month 
period. Specimens from the same patient that were collected <2 weeks apart and those 
from patients admitted to the hospital <48 hours before BAL sampling were excluded. 
Indications to BAL included respiratory symptoms, new infiltrates on chest X-ray or routine 
follow-up in lung transplant recipients (at month 1 post-transplantation and subsequently at 
three month intervals). The following features were collected: immune and  transplant 
status, comorbidities, coinfections (evaluated by a diagnostic panel including bacterial, 
fungal, and other viral agents [13]), admittance and length of stay at ICU, total length of 
hospital stay, mechanical ventilation (MV), VAP (diagnosed according to CDC definitions 
[14]), mortality within 28 days. The occurrence of HSV-1 and 2 was evaluated by real-time 
PCR (R-geneTM, Argene, France) targeting the US7 and US2 genes, respectively. 
According to our center’s practice, HSV diagnostics also included rapid shell vial isolation 
on Vero cell cultures [15]. For statistical analysis, the chi-square test and t-test were used, 
as appropriate. A p value <0.05 was considered significant.  
Overall, HSV-1-DNA was detected in 86/342 (25.1%) specimens from 76/237 (32.1%) 
patients and HSV-2 in three (0.9%) from as many patients. HSV infection was confirmed 
by viral isolation in 85% of the specimens, with discordant results occurring mostly in 
cases in which acyclovir treatment had been initiated. HSV-1 occurrence and load in 
relation to main clinical features are reported in Table 1. A significant difference of  
prevalence and load was found in relation to admission to ICU (p = 0.007 and 0.002, 
respectively), MV (p = 0.04 and 0.0008), and mortality within 28 days (p = 0.004 and 
0.018); as well as in relation to the occurrence of coinfections evaluated in single 
specimens (p = 0.002 and 0.07), with other herpesviruses and bacterial agents being the 
most commonly detected. No significant difference was found as regards immune and 
transplant status, and presence of comorbidities. Also length of stay in ICU and total length 
of stay in hospital were not significantly different between HSV-1 positive (means: 28 and 
43 days, respectively) and negative (19 and 32, respectively) patients. In the subgroup of 
follow-up specimens from lung transplant recipients, in comparison to those collected for 
symptomatic indication, HSV-1 occurrence and load were not significantly different. As 
regards VAP, 9/21 (42.9%) cases were positive to HSV-1 and six (66.7%) died within a 
period ranging from 3 to 120 days (main agents: S. aureus, P. aeruginosa, S. pneumonia, 
E. coli, gram-negative bacteria). As regards the impact of high level viral replication, the 
prevalence of admission to ICU (p<0.0001), MV (p = 0.016) and death within 28 days (p = 
0.013) was significantly higher in the presence of a HSV-1 load ≥105  copies/mL; while no 
significant difference was found in relation to the immune status (Figure 1). Multiple 
specimens were available for 46 patients (range, 2-7), 19 of which resulted positive in at 
least one specimen and 11 in consecutive samples. Among patients with consecutively 
positive specimens, five were asymptomatic lung transplant recipients with viral loads <103 
copies/ml and usually persisting at the subsequent evaluation at 3 months; six were from 
ICU and evidenced a typical pattern of HSV-1 kinetics with positivity appearing within one 
week of MV and an exponential increase in viral load (about 5 logs) in subsequent 
specimens, as reported in other studies [10]. The treatment was started at the clinician’s 
discretion and no significant difference in outcome or decay in viral load was found 
between acyclovir-treated and not treated patients. Interestingly, HSV-1 was positive on 
BAL specimens (by both molecular methods and viral isolation), in 6/10 ICU patients with 
influenza AH1N1v. Five of these patients died within two weeks from BAL sampling and 
three of them (60%) resulted HSV-1-positive also on autopsy lung samples by both 
molecular methods and rapid viral isolation.  
Overall, HSV-1 was detected quite frequently, with rates similar to those previously 
reported (up to 35%) [5,6,10]. No significant difference of prevalence according to immune 
and transplant status, as well as comorbidities, was found; whereas HSV-1 prevalence 
and load were significantly higher in the presence of critical features such as admission to 
ICU, MV and mortality within 28 days. The evaluation of the subgroup of surveillance 
specimens in lung transplant recipients, that may be considered as controls with 
immunosuppression, but no traumatic or inflammatory stimulus, evidenced no significant 
difference in comparison to specimens collected from symptomatic patients, although the 
low number of specimens should be considered. Interestingly, HSV-1 infection was quite 
frequent in the presence of VAP, with prevalence rate higher than that previously reported 
[11]. However, given the smaller number of patients in our series, further studies should be 
performed, particularly in consideration of the poor outcome. As previously suggested [6], 
a viral load ≥105 copies/mL was associated to severity features, in contrast to the lack of 
association to immunocompromised conditions. The relevance of these findings should be 
more appropriately evaluated also considering the occurrence of coinfections. It has been 
suggested that the mucosal damage associated with intubation and MV is a potential 
trigger for HSV-1 reactivation and that aspiration from the upper respiratory tract 
represents the main source of lower respiratory tract infections. Nevertheless, no 
conclusion can be drawn as to the causative role in lung and further studies on tissue 
specimens and performing randomized medical intervention analyses are needed [16]. 
 Acknowledgments 
Part of the results of this study have been presented previously as oral communication at 
the 21st ECCMID (Milan, Italy 7-10 May 2011). 
 
Transparency declaration 
Source of funding: none. Data were generated as part of routine activities. 
Conflict of interest: none. 
References 
1. Simoons-Smit AM, Kraan EM, Beishuizen A, Strack van Schijndel RJ, Vandenbroucke-
Grauls CMl. Herpes simplex virus type 1 and respiratory disease in critically-ill patients: 
real pathogen or innocent bystander? Clin Microbiol Infect 2006; 12: 1050-1059. 
2. Bruynseels P, Jorens PG, Demey HE, Goossens H, Pattyn SR, Elseviers MM, Weylaer 
J, Bossaert LL, Mentens Y, Ieven M. Herpes simplex virus in the respiratory tract of 
critical care patients: a prospective study. Lancet 2003; 362: 1536-1541. 
3. van den Brink JW, Simoons-Smit AM, Beishuizen A, Girbes AR, Strack van Schijndel 
RJ, Groeneveld AB. Respiratory herpes simplex virus type 1 infection/colonisation in 
the critically ill: marker or mediator? J Clin Virol 2004; 30: 68-72. 
4. Daubin C, Vincent S, Vabret A, du Cheyron D, Parienti JJ, Ramakers M, Freymuth F, 
Charbonneau P. Nosocomial viral ventilator-associated pneumonia in the intensive 
care unit: a prospective cohort study. Intensive Care Med 2005; 31: 1116-1122. 
5. Luyt CE, Combes A, Deback C, Aubiriot-Lorton M-H, Nieszkowska A, Trouillet JL, 
Capron F, Agut H, Gibert C, Chastre J. Herpes Simplex Virus lung infection in patients 
undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med 2007; 175: 
935-942. 
6. Linssen CF, Jacobs JA, Stelma FF, van Mook WN, Terporten P, Vink C, Drent M, 
Bruggeman CA, Smismans A. Herpes simplex virus load in bronchoalveolar lavage 
fluid is related to poor outcome in critically ill patients. Intensive Care Med 2008; 34: 
2202-2209. 
7. Ong GM, Lowry K, Mahajan S, Wyatt DE, Simpson C, O’Neill HJ, McCaughey C, Coyle 
PV. Herpes simplex type 1 shedding is associated with reduced hospital survival in 
patients receiving assisted ventilation in a tertiary referral intensive care unit. J Med 
Virol 2004; 72: 121-125. 
8. Engelmann I, Gottlieb J, Meier A, Sohr D, Ruhparwar A, Henke-Gendo C, Gastmeier P, 
Welte T, Schulz TF, Mattner F. Clinical relevance of and risk factors for HSV-related 
tracheobronchitis or pneumonia: results of an outbreak investigation. Critical Care 
2007; 11: R119. 
9. Gooskens J, Templeton KE, Claes EC, von Bussel MJ, Smit VT, Kroes AC. 
Quantitative detection of herpes simplex virus DNA in the lower respiratory tract. J Med 
Virol 2007; 79: 597-604. 
10. De Vos N, Van Hoovels L, Vankeerberghen A, Van Vaerenbergh K, Boel A, Demeyer I, 
Creemers L, De Beenhouwer H. Monitoring of herpes simplex virus in the lower 
respiratory tract of critically ill patients using real-time PCR: a prospective study. Clin 
Microbiol Infect 2009; 15: 358-363. 
11. Bouza E, Giannella M, Torres MV, Catalán P, Sánchez-Carrillo C, Hernandez RI, 
Muñoz P. Herpes simplex virus: a marker of severità in bacterial ventilator-associated 
pneumonia. J Crit Care 2011; 26: 432e1-6. 
12. Scheithauer S, Manemann AK, Krüger S, Häusler M, Krüttgen A, Lemmen SW, Ritter 
K, Kleines M. Impact of herpes simplex virus detection in the respiratory specimens of 
patients with suspected viral pneumonia. Infection 2010; 38: 401-405. 
13. Costa C, Bergallo M, Astegiano S, Sidoti F, Terlizzi ME, Gambarino S, Curtoni A, 
Simeone S, Solidoro P, Cavallo R. Detection of human rhinoviruses in the lower 
respiratory tract of lung transplant recipients. Arch Virol 2011; 156: 1439-1443. 
14. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for 
nosocomial infections. Am J Infect Control 1988; 16: 128-140. 
15. Costa C, Libertucci D, Solidoro P, Sinesi F, Bergallo M, Margio S, Piana F, Baldi S, 
Cavallo R. Rapid shell vial culture for the detection of respiratory viruses from 
bronchoalveolar lavage in immunocompromised patients. Panminerva Med 2007; 49: 
1-6. 
16. López-Giraldo A, Sialer S, Esperatti M, Torres A. Viral-reactivated pneumonia during 
mechanical ventilation: is there need for antiviral treatment? Front Pharmacol 2011; 2: 
66.  
 
Table 1. Results of HSV-1 DNA detection in bronchoalveolar lavage (BAL) 
specimens and association to clinical features of study population. For evaluation of 
mean viral load, peak values in each patient were considered. As regards indication to 
BAL (see text for details) and presence of coinfections, single episodes and not patients 
were evaluated. N, number; n.s., not significant; yrs, years; ICU, intensive care unit.  
Table 1 
 
 HSV-1 pos. 
N (%) 
P HSV-1 
Mean viral load (copies/mL BAL) 
p 
Total number 
  patients     237 
  specimens     342 
 
73 (30.8%) 
86 (25.1%) 
 
 
- 
 
5.7 x 10
5 
 
5.6 x 10
5
 
 
 
- 
Age 
   ≤50 yrs     76   
   >50 yrs     161 
 
23 (30.2%) 
50 (31.1%) 
 
 
0.98 
 
4.4 x 10
5 
5.8 x 10
5
 
 
 
0.49 
Indication to BAL* 
  Symptomatic     331 
  Surveillance     11   
 
83 (25.1%) 
3 (27.3%) 
 
 
0.85 
 
5.8 x 10
5
 
9 x 10
2
 
 
 
0.49 
Admission to ICU 
  Yes     99 
  No     138 
 
37 (37.4%) 
36 (26.1%) 
 
 
0.007 
 
1.03x10
6  
8.8x10
4
 
 
 
0.002 
Immune status 
  competent     123 
  compromised     114 
 
38 (30.9 %) 
35  (30.7%) 
 
 
0.91 
 
2.6 x 10
5
 
1.9 x 10
5
 
 
 
0.89 
Transplant status 
  yes     78 
  no     159 
 
24  (30.8%) 
49 (30.8%) 
 
 
0.88 
 
4.6 x 10
5 
6.2 x 10
5
 
 
 
0.62 
Comorbidities 
  yes     73 
  no     164  
 
23 (31.5%) 
52 (31.7%) 
 
 
0.90 
 
8.4 x 10
5
  
3.5 x 10
5
 
 
 
0.13 
Mechanical ventilation 
  yes     72 
  no     165 
 
30 (41.6%) 
45 (27.3%) 
 
 
0.04 
 
1.2x10
6
  
1.4x10
5
 
 
 
0.0008  
Coinfections* 
  yes     203 
  no     139 
 
64 (31.5%) 
22 (15.8%) 
 
 
0.002 
 
7.3 x 10
5 
8.4 x 10
4 
 
 
0.07 
Death within 28 days 
  yes     39 
  no     198 
 
20 (51.3%) 
53 (26.7%) 
 
 
0.004 
 
1.2 x 10
6 
3.3 x 10
5
 
 
 
0.018 
Figure 1. Prevalence of admission to intensive care unit (ICU), mechanical 
ventilation, immunosuppression, and death within 28 days according to viral load of 
HSV-1 in bronchoalveolar lavage specimens: ≥105 (dark bars) vs <105 copies/ml 
(white bars). 
p 
 
p <0.0001 
 
p = 0.016 
 
p = 0.6 
 
p = 0.013 
 
 
